SCHEMBL2898616

SCHEMBL2898616

CCOC(=O)c1cnc(C(C)C)[nH]c1=O

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.56
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 6/20 0.53
L3MBTL1 Q9Y468 5/20 0.53
MAPT P10636 4/20 0.53
POLB P06746 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
LMNA P02545 2/20 0.51
NPC1 O15118 1/20 0.48
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA6 P23280 2/20 0.47
CA7 P43166 2/20 0.47
CA13 Q8N1Q1 2/20 0.47
MAPK1 P28482 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NR1H2 P55055 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13724398 0.89 ALDH1A1 (0.54) GAAALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL3824059 0.89 GAA (0.54) GAAALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL13724507 0.87 ALDH1A1 (0.53) GAAALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL23900679 0.83 KDM4E (0.46) GAAALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL2902593 0.82 ALDH1A1 (0.66) GAAALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL1014580 0.81 KDM4E (0.58) GAAALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL23900636 0.79 ALDH1A1 (0.63) GAAALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL6706506 0.79 GAA (0.63) GAAALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL7997265 0.79 KDM4E (0.55) GAAALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL18585976 0.79 ALDH1A1 (0.59) GAAALDH1A1KDM4EL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202228-B1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL (JP) 2014-12-10 EP disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME REN, ACE, AGT GAA 530/4885ALDH1A1 897/4885KDM4E 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.